Tofacitinib citrate?

Tofacitinib citrate is the citrate salt of tofacitinib, a small-m molecule that inhibits JAK enzymes (primarily JAK1 and JAK3, with some JAK2 activity at higher doses). It’s an oral disease-modifying drug used to treat several autoimmune conditions.

Key points:
- Brand/name: Xeljanz (the citrate salt is the form used in tablets).
- Mechanism: JAK inhibitor — blocks signaling of many inflammatory cytokines.
- Indications (adult use in many places; check your country’s labeling):
- Rheumatoid arthritis (RA)
- Psoriatic arthritis (PsA)
- Ulcerative colitis (UC)
- Some jurisdictions also have pediatric approvals for certain conditions
- Common dosing (varies by indication and region):
- RA/PsA: typically around 5 mg taken by mouth twice daily; an extended-release option (often 11 mg once daily) exists in some markets.
- UC: induction often uses a higher dose (e.g., 10 mg twice daily for a short period) followed by a maintenance dose (often lower, like 5 mg twice daily). Dosing can differ by region.
- Important safety considerations:
- Infections: increased risk of serious infections, including tuberculosis and shingles.
- Cancer risk: potential for malignancies with long-term use.
- Blood clots and cardiovascular concerns: risk may be higher at certain doses or in some patients.
- Lab changes: possible increases in lipid levels and liver enzymes; may cause anemia or thrombocytopenia.
- Other: may interact with other immunosuppressants; avoid live vaccines during treatment; use contraception if pregnancy is possible.
- Common side effects: upper respiratory infections, headaches, diarrhea, nausea, high blood pressure, elevated cholesterol, and low blood counts in some people.
- Monitoring and safety: TB screening before starting; baseline and periodic CBC, LFTs, and lipid panel; monitor for signs of infection; consider vaccination status; pregnancy considerations apply.

If you tell me your country/region and the condition you’re asking about (RA, PsA, UC, etc.), I can give you more precise, up-to-date dosing, monitoring, and safety details from the current labeling.